Harnessing the power of immune cells, especially T cells, to enhance anti-tumor activities
has become a promising strategy in clinical management of hematologic malignancies. The …

CD38 is highly and uniformly expressed on multiple myeloma (MM) cells, and at relatively
low levels on normal lymphoid and myeloid cells, and in some tissues of nonhematopoietic …

Background Lenalidomide and bortezomib frontline exposure has raised a growing need for
novel treatments for patients with relapsed or refractory multiple myeloma. Carfilzomib in …

Background Bortezomib, thalidomide, and dexamethasone (VTd) plus autologous stem-cell
transplantation is standard treatment in Europe for transplant-eligible patients with newly …

Background BCMA-specific chimeric antigen receptor-T cells (CAR-Ts) have exhibited
remarkable efficacy in refractory or relapsed multiple myeloma (RRMM); however, primary …

Background Daratumumab, a human IgGκ monoclonal antibody that targets CD38, induces
direct and indirect antimyeloma activity and has shown substantial efficacy as monotherapy …

Multiple myeloma (MM) accounts for 1% of all cancers and $10% of all haematological
malignancies. The incidence in Europe is 4.5–6.0/100 000/year with a median age at …

In POLLUX, daratumumab (D) plus lenalidomide/dexamethasone (Rd) reduced the risk of
disease progression or death by 63% and increased the overall response rate (ORR) versus …

Daratumumab plus pomalidomide and dexamethasone (pom-dex) was evaluated in patients
with relapsed/refractory multiple myeloma with≥ 2 prior lines of therapy who were refractory …

Background Intravenous daratumumab for treatment of patients with multiple myeloma
involves a lengthy infusion that affects quality of life, and infusion-related reactions are …